True North Therapeutics nabs $45 mln Series D

South San Francisco-based True North Therapeutics, a clinical-stage biopharmaceutical company, has closed $45 million in Series D funding. The investors included HBM Healthcare Investments, Redmile Group, Perceptive Advisors and Franklin Templeton Investments.

Source: Press Release